Skip to NavigationSkip to content

remdesivir

Gilead's promising COVID-19 drug remdesivir shows benefit in 68% of hospitalised patients

Gilead has provided an update on its ongoing efforts against the novel coronavirus, revealing data from a cohort analysis of its antiviral therapy remdesivir, one of the most promising treatments for patients hospitalised by COVID-19.

The findings, published in The New England Journal of Medicine, were drawn from 53 participants hospitalised due to severe complications with COVID-19, 34 of which were being treated with mechanical ventilation at baseline, including four patients who were also receiving extracorporeal membrane oxygenation.

WHO launches "historic" multinational study to investigate most promising COVID-19 therapies

Image credit: Leif Jørgensen / CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)

The World Health Organization continues to push forward in the global fight against the novel coronavirus, and has announced the enrolment of the first patients in a set of “historic” multinational clinical trials to investigate four of the most promising therapies against the pathogen.

The first participants were recruited in Norway and Spain, with further patients due to join the study. The trials, known collectively as SOLIDARITY, aim to build a base of clinical evidence for what have been touted as some of the most promising treatments against the disease.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches